Major companies are focusing on leveraging technological advancements such as the development of novel reversal agents. This innovative approach enhances treatment efficacy and boosts patient safety. To illustrate, in March 2022, AstraZeneca plc, a leading UK-based pharmaceutical and biotechnology company, announced the approval of Ondexxya andexanet alfa in Japan. The drug is designed to reverse the effects of Factor Xa inhibitors apixaban, rivaroxaban, edoxaban during severe bleeds. Being the first of its kind in Japan, the approval represented a milestone, addressing the risk of major bleeding linked with these widely used anticoagulant drugs.